(19) |
|
|
(11) |
EP 0 000 151 B1 |
(12) |
EUROPEAN PATENT SPECIFICATION |
(45) |
Mention of the grant of the patent: |
|
20.05.1981 Bulletin 1981/20 |
(22) |
Date of filing: 15.06.1978 |
|
|
(54) |
1-Substituted aminoindolines, process for their production and pharmaceutical compositions
containing them
1-Substituierte Aminoindoline, Verfahren zu ihrer Herstellung und diese Verbindungen
enthaltende pharmazeutische Zusammensetzungen
Aminoindolines substituées en position 1, procédé de leur production et compositions
thérapeutiques les contenant
|
(84) |
Designated Contracting States: |
|
BE CH DE FR GB LU NL SE |
(30) |
Priority: |
28.06.1977 CH 7915/77
|
(43) |
Date of publication of application: |
|
10.01.1979 Bulletin 1979/01 |
(71) |
Applicant: SANDOZ AG |
|
4002 Basel (CH) |
|
(72) |
Inventors: |
|
- Bormann, Gerhard, Dr.
CH-4142 Münchenstein (CH)
- Berthold, Richard, Dr.
CH-4103 Bottmingen (CH)
|
|
|
|
Note: Within nine months from the publication of the mention of the grant of the European
patent, any person may give notice to the European Patent Office of opposition to
the European patent
granted. Notice of opposition shall be filed in a written reasoned statement. It shall
not be deemed to
have been filed until the opposition fee has been paid. (Art. 99(1) European Patent
Convention).
|
[0001] The present invention relates to 1-substituted aminoindoline derivatives.
[0002] In accordance with the invention there are provided compounds of formula I,
wherein
one of R1 and R2 is hydrogen and the other is hydrogen or alkyl of 1 to 4 carbon atoms,
R3 is hydrogen or alkyl of 1 to 4 carbon atoms, in the 2- or 3-position,
R4 and R5 independently are hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon
atoms, alkylthio of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35, and
n is 2, 3 or 4.
[0003] Alkyl, alkoxy and alkylthio preferably contain 1 or 2, especially 1 carbon atom.
Halogen is preferably chlorine.
Ri, R2, R3 and R5 are preferably hydrogen. R4 is preferably hydrogen, alkyl or halogen, especially hydrogen.
R3 is preferably in the 3 position of the indoline nucleus.
R4 is preferably in the 4,5 or 6, especially in the 4 or 5, preferably in the 4-position.
n is preferably 2.
[0004] In accordance with the invention, a compound of formula I may be obtained by a process
comprising cyclizing a compound of formula II,
wherein
R1 to R5 and n are as defined above and
X is a leaving group.
[0005] The process according to the invention may be effected in a manner analogous to known
methods for cyclizing analogous amino derivatives. X is e. g. a group -NHR
a, wherein R
a is alkyl of 1 to 4 carbon atoms, especially methyl, or R
a is hydrogen. The reaction is preferably effected in an inert solvent such as methanol
or ethanol, or, when the amine of formula IV (see below) is liquid at the reaction
temperature, the reaction is conveniently effected in the absence of any additional
solvent. The reaction is preferably effected in the presence of a mineral acid such
as hydrochloric or hydroiodic acid. The reaction temperature may be from room temperature
to about 150°C and is preferably at least 50° C, e. g. the boiling temperature of
the reaction mixture.
[0006] The compounds of formula I may be isolated and purified in accordance with known
methods.
[0007] The compounds of formula I may be present in free form, or in the form of acid addition
salts. Acid addition salt forms, for example, the hydrochloride or hydrogen maleate,
may be produced from the free form in known manner, and vice-versa.
[0008] The compounds of formula I may also be present in tautomeric form, i. e. with the
double bond adjacent to one of the other two nitrogen atoms of the guanidine moiety,
insofar as this nitrogen atom is not substituted by an alkyl group R
i or R
2. It is to be appreciated that such tautomeric forms also fall under the scope of
formula I.
[0009] The production of the starting materials may be effected in known manner.
[0010] A compound of formula II may e. g. be produced by reacting a compound of formula
III,
wherein R
3 to R
5 and X are as defined above and the group -S-Y is a leaving group, with a compound
of formula IV,
wherein R
i, R
2 and n are as defined above.
[0011] Y may e. g. be alkyl of 1 to 4 carbon atoms, preferably methyl. The reaction conditions
may be chosen such as to be identical with the conditions for cyclization according
to the invention. The compounds of formula III are then advantageously reacted with
the compounds of formula IV to give directly the corresponding compounds of formula
I, without intermediate isolation of the compounds offormula II.
[0012] When in the compounds of formula III Y is alkyl of 1 to 4 carbon atoms and X is a
grcup -NH-R
a, the reaction conditions for producing compounds of formula I directly from corresponding
compounds of formula III are analogous to known reaction conditions for the production
of a 1-(indolin-1-yl)-guanidine derivative from a 1-(indolin-1-yl)-2-(lower)alkylisothiourea.
[0013] Insofar as the production of the starting materials is not described, these are known
or may be produced and purified in accordance with known processes, or in a manner
analogous to the processes described above or analogous to known processes.
[0014] In the following non-limitative Examples all temperatures are indicated in degrees
Centigrade and are uncorrected.
Example 1
1-(Imidazolidin-2-ylidenamino)indoline
[0015] To 10 g 1-(indolin-1-yl)-2-methylisothiourea hydrochloride dissolved in 40 ml ethanol
are added 8 ml ethylene diamine and the reaction mixture is boiled for 6 hours with
stirring. The mixture is then evaporated to dryness and the residue is extracted from
a 1 M solution of sodium hydroxide with methylene chloride. The organic phase is then
dried over magnesium sulphate and evaporated. The title compound is obtained (M. P.
of the hydrogen maleate 171―172° ― from ethanol/ether).
[0016] The starting material is obtained as follows:
1-Aminoindoline is reacted with benzoyl isothiocyanate in boiling tetrahydrofurane
and, after saponification of the product over 15 minutes with diluted sodium hydroxide
under reflux, 1-(indolin-1-yl)thiourea (M. P. 225-227° - from methanol) is obtained.
This product is converted into 1-(indolin-1-yl)-2-methylisothiourea hydroiodide by
heating up for 1 hour with methyl iodide in methanol. The free base is obtained by
addition of aqueous sodium hydroxide and is further reacted with a 2N methanolic solution
of hydrochloric acid to give 1-(indolin-1-yl)-2-methylisothiourea hydrochloride (M.
P. 227-229° - from methanol/ether).
[0017] The following compounds of formula I are obtained in a manner analogous to Example
1, using the corresponding starting materials of formula III, wherein Y is methyl
and X is ―NH
2 or ―NH―CH
3, and of formula IV:
[0018] The compounds of formula I exhibit pharmacological activity. In particular, the compounds
possess vasoconstricting activity, as indicated by standard tests. For example, this
activity may be observed in vivo in rats treated in accordance with the principles
of J. S. Gillespie and T. C. Muir, Br. J. Pharmac. Chemother. (1967) 30, 78-87): a
pressor effect is elicited following i. v. administration of from about 0.02 to about
50 µg/kg, particularly of from about 0.02 to about 0.5 µg/kg of the compounds.
[0019] The compounds are therefore indicated for use as vasoconstricting agents, e. g. for
the prophylaxis and treatment of vascular headaches such as migraine, and of orthostatic
disorders such as orthostatic hypotension and its symptoms, such as vertigo.
[0020] For this use an indicated daily dose is from about 0.0025 to about 1 mg, conveniently
administered in divided doses 2 to 4 times a day in unit dosage form containing from
about 0.0005 to about 0.5 mg, or in sustained release form.
[0021] The activity of the compound of Example 1 is especially interesting.
[0022] The compounds of formula I may be administered in free form or in pharmaceutically
acceptable acid addition salt form. Such forms exhibit the same order of activity
as the free form. The present invention also provides a pharmaceutical composition
comprising a compound of formula I, in free form or in pharmaceutically acceptable
salt form, in association with a pharmaceutical carrier or diluent. Such compositions
may be in the form of, for example, a solution or a tablet.
1. A process for the production of a compound of formula I,
wherein
one of R1 and R2 is hydrogen and the other is hydrogen or alkyl of 1 to 4 carbon atoms,
R3 is hydrogen or alkyl of 1 to 4 carbon atoms, in the 2- or 3-position,
R4 and R5 independently are hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon
atoms, alkylthio of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35,
and
n is 2, 3 or 4,
or a tautomeric form thereof, which comprises cyclizing a compound of formula I
wherein
R1 to R5 and n are as defined above and
X is a leaving group.
2. A compound of formula I, as defined in claim 1, or a tautomeric form thereof.
3. A compound of claim 2, wherein RI to R5 are hydrogen and n is 2.
4. A compound of claim 2, wherein Ri, R2 and R5 are hydrogen and n is 2.
5. A compound of claim 4, wherein R3 is hydrogen and R4 is 5-chloro, or R3 is 2-methyl and R4 is hydrogen.
6. A compound of claim 4, wherein R3 is 3-methyl and R4 is hydrogen, or R3 is hydrogen and R4 is 4-methyl.
7. A compound of claim 4, wherein R3 is hydrogen and R4 is 4-methoxy, or R3 is hydrogen and R4 is 7-methyl.
8. A compound according to any one of claims 2 to 7, in free form.
9. A compound according to any one of claims 2 to 7, in acid addition salt form.
10. A pharmaceutical composition comprising a compound according to any one of claims
2 to 7 in free form or in pharmaceutically acceptable acid addition salt form, in
association with a pharmaceutical carrier or diluent.
11. A compound of claim 2, for use in a method for treatment of the human or animal
body by therapy.
1. Ein Verfahren zur Herstellung einer Verbindung der Formel I,
worin
eines von R1 und R2 Wasserstoff und das andere Wasserstoff oder Alkyl mit 1 -4 Kohlenstoffatomen bedeutet,
R3 Wasserstoff oder in 2- oder 3-Stellung ständiges Alkyl mit 1-4 Kohlenstoffatomen
bedeutet,
R4 und R5 unabhängig voneinander für Wasserstoff, Alkyl mit 1-4 Kohlenstoffatomen, Alkoxy mit
1-4 Kohlenstoffatomen, Alkylthio mit 1-4 Kohlenstoffatomen oder Halogen mit einer
Ordnungszahl von 9 bis 35 stehen, und
n für die Zahl 2, 3 oder 4 steht,
oder einer ihrer tautomeren Formen, beinhaltend die Cyclisierung einer Verbindung
der Formel II,
worin
R1 bis R5 und n obige Bedeutung besitzen und
X für eine Abgangsgruppe steht.
2. Eine Verbindung der Formel wie in Anspruch 1 definiert, oder eine ihrer tautomeren
Formen.
3. Eine wie in Anspruch 2 definierte Verbindung, in der R1 bis R5 Wasserstoff bedeuten und n für die Zahl 2 steht.
4. Eine wie in Anspruch 2 definierte Verbindung, in der Ri, R2 und R5 Wasserstoff bedeuten und n für die Zahl 2 steht.
5. Eine wie in Anspruch 4 definierte Verbindung, in der R3 Wasserstoff bedeutet und R4 für 5-Chlor steht, oder R3 2-Methyl bedeutet und R4 für Wasserstoff steht.
6. Eine wie in Anspruch 4 definierte Verbindung, in der R3 3-Methyl bedeutet und R4 für Wasserstoff steht, oder R3 Wasserstoff bedeutet und R4 für 4-Methyl steht.
7. Eine wie in Anspruch 4 definierte Verbindung, in der R3 Wasserstoff bedeutet und R4 für 4-Methoxy steht, oder R3 Wasserstoff bedeutet und R4 für 7-Methyl steht.
8. Eine Verbindung, wie in irgendeinem der Ansprüche 2 bis 7 definiert, in freier
Form.
9. Eine Verbindung, wie in irgendeinem der Ansprüche 2 bis 7 definiert, in Säureadditionssalzform.
10. Eine pharmazeutische Zusammensetzung, enthaltend eine Verbindung, wie in irgendeinem
der Ansprüche 2 bis 7 definiert, in freier Form oder in physiologisch verträglicher
Säureadditionssalzform, zusammen mit einem Träger- bzw. Verdünnungsmittel.
11. Eine Verbindung, wie in Anspruch 2 definiert, zur Anwendung in einem Verfahren
zur therapeutischen Behandlung des menschlichen oder tierischen Körpers.
1. Un procédé de préparation d'un composé de formule I
dans laquelle
l'un des symboles R1 et R2 est l'hydrogène et l'autre est l'hydrogène ou un groupe alkyle de 1 à 4 atomes de
carbone,
R3 est l'hydrogène ou un groupe alkyle de 1 à 4 atomes de carbone, en position 2 ou
3,
R4 et R5 signifient indépendamment l'hydrogène, un groupe alkyle de 1 à 4 atomes de carbone,
alcoxy de 1 à 4 atomes de carbone, alkylthio de 1 à 4 atomes de carbone ou un halogène
d'un nombre atomique compris entre 9 et 35, et
n signifie 2, 3 ou 4,
ou une forme tautomère de ce composé, comprenant la cyclisation d'un composé de formule
Il
dans laquelle R
i à R
5 et n sont tels que définis ci-dessus et X est un groupe susceptible d'être éliminé.
2. Un composé de formule I, tel que défini à la revendication 1, ou une forme tautomère
de ce composé.
3. Un composé de la revendication 2, dans lequel Ri à R5 sont l'hydrogène et n est 2.
4. Un composé de la revendication 2, dans lequel Ri, R2 et R5 sont l'hydrogène et n est 2.
5. Un composé de la revendication 4, dans lequel R3 est l'hydrogène et R4 est un atome de chlore en position 5, ou R3 est un groupe méthyle en position 2 et R4 est l'hydrogéne.
6. Un composé de la revendication 4, dans lequel R3 est un groupe méthyle en position 3 et R4 est l'hydrogène, ou R3 est l'hydrogène et R4 est un groupe méthyle en position 4.
7. Un composé de la revendication 4, dans lequel R3 est l'hydrogène et R4 est un groupe méthoxy en position 4, ou R3 est l'hydrogène et R4 est un groupe méthyle en position 7.
8. Un composé selon l'une quelconque des revendications 2 à 7, sous forme libre.
9. Un composé selon l'une quelconque des revendications 2 à 7, sous forme de sel d'addition
d'acide.
10. Une composition pharmaceutique comprenant un composé selon l'une quelconque des
revendications 2 à 7 sous forme libre ou sous forme d'un sel d'addition d'acide acceptable
du point de vue pharmaceutique, en association avec un excipient ou diluant pharmaceutique.
11. Un composé de la revendication 2, pour l'utilisation dans une méthode de traitement
thérapeutique du corps humain ou animal.